Stock BIO3 BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

Biotest AG Stock

Equities

BIO3

DE0005227235

Pharmaceuticals

Market Closed - Xetra
Other stock markets
 11:36:24 2025-02-14 am EST 		5-day change 1st Jan Change
28.30 EUR -2.08% Intraday chart for Biotest AG -2.75% +4.81%
Jan. 09 Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration CI
Nov. 14 Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI

Valuation: Biotest AG

Capitalization 1.37B 1.44B 1.29B 1.14B 2.03B 124B 2.26B 15.35B 5.69B 52.02B 5.38B 5.28B 218B P/E ratio 2024 *
-278x
P/E ratio 2025 * 18.8x
Enterprise value 2.03B 2.13B 1.91B 1.69B 3.02B 185B 3.35B 22.78B 8.44B 77.17B 7.99B 7.83B 324B EV / Sales 2024 *
3.19x
EV / Sales 2025 * 2.85x
Free-Float
51.43%
Yield 2024 *
0.07%
Yield 2025 * 2.19%
More valuation ratios * Estimated data

Chart: Biotest AG

Dynamic Chart

Latest news: Biotest AG

Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration Jan. 09 CI
Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 14 CI
Biotest Signs Distribution Deal in Latin America for Hemophilia A Treatment 24-10-29 MT
Kedrion Biopharma Inc. and Biotest Ag Complete Long-Term Exclusive Distribution Agreement for Yimmugo in the Us 24-10-02 CI
Biotest CFO Steps Down; Interim Successor Named 24-09-12 MT
Biotest Chief Scientific Officer to Step Down 24-08-28 MT
Biotest Aktiengesellschaft Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 24-08-06 CI
Kedrion Biopharma Inc. Selects by Biotest to Distribute Its Immunoglobulin Yimmugo in the U.S. Following Recent FDA Approval 24-07-01 CI
Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies 24-06-17 CI
Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024 24-05-07 CI
Biotest Launches New Plasma Collection Center in Germany 24-04-19 MT
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 24-03-27 CI
Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 23-11-02 CI
More news

Press Releases: Biotest AG

Biotest : articles of association - as of May 2024 PDF, 126 KB Jan. 15 PU
Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Jan. 09 EQ
Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations Nov. 15 EQ
Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million Nov. 14 EQ
Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged Nov. 14 EQ
More press releases

News in other languages: Biotest AG

Wichtiger Meilenstein für Biotest: Zulassungsantrag für Fibrinogen in den USA bei der US Food and Drug Administration (FDA) eingereicht Jan. 09
Wichtiger Meilenstein für Biotest: Zulassungsantrag für Fibrinogen in den USA bei der US Food and Drug Administration (FDA) eingereicht Jan. 09
Wirtschaftsminister Mansoori und Oberbürgermeister Benz besuchen Plasmazentrum von Biotest in Darmstadt und rufen zur Plasmaspende auf Nov. 15
Wirtschaftsminister Mansoori und Oberbürgermeister Benz besuchen Plasmazentrum von Biotest in Darmstadt und rufen zur Plasmaspende auf Nov. 15
Biotest steigert Umsatz in den ersten 9 Monaten um 4,5% auf 523 Mio. Euro Nov. 14
More news

Quotes and Performance

1 day-2.08%
1 week-2.75%
Current month+1.07%
1 month+2.54%
3 months+6.79%
6 months+10.12%
Current year+4.81%
More quotes

Course Extremes

1 week
28.30
Extreme 28.3
29.10
1 month
26.40
Extreme 26.4
29.60
Current year
25.00
Extreme 25
29.60
1 year
22.80
Extreme 22.8
29.90
3 years
22.80
Extreme 22.8
37.00
5 years
17.00
Extreme 17
44.50
10 years
10.31
Extreme 10.305
44.50
More quotes

Managers and Directors: Biotest AG

Director TitleAgeSince
Peter Janssen CEO
 Chief Executive Officer 59 2023-12-31
Christian Polus CTO
 Chief Tech/Sci/R&D Officer - -
Oliver Hein CMP
 Compliance Officer - 2016-12-31
Manager TitleAgeSince
Tomás Dagá Gelabert BRD
 Director/Board Member 69 2022-05-31
Raimon Grifols Roura BRD
 Director/Board Member 62 2023-05-08
Bernhard R. M. Ehmer CHM
 Chairman 70 2022-05-04
More insiders

Biopharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
BIOTEST AG Stock Biotest AG
-2.08%-2.75%-1.05%-23.51% 1.44B
CSL LIMITED Stock CSL Limited
+1.14%-5.85%-8.98%+3.38% 77.49B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.90%+17.90%+40.69%+56.37% 58.07B
UCB Stock UCB
-3.58%-4.65%+91.85%+112.44% 37.08B
BIOGEN INC. Stock Biogen Inc.
-0.81%-2.83%-37.78%-35.85% 20.17B
ALTEOGEN INC. Stock ALTEOGEN Inc.
-1.85%-5.48%+327.83%+820.50% 13.66B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
-0.19%+0.65%+77.58%+141.21% 13.61B
INCYTE CORPORATION Stock Incyte Corporation
+0.59%-5.03%+21.61%+6.63% 13.55B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
+0.67%+1.46%-24.58%-27.94% 12.28B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
+4.31%+0.76%+9.19%-34.39% 11.4B
Average +0.01%-2.09%+49.64%+101.88% 25.88B
Weighted average by Cap. +0.33%-2.75%+38.42%+75.11%
See all sector performances

Financials

2024 *2025 *
Net sales 636M 668M 600M 530M 946M 57.86B 1.05B 7.14B 2.65B 24.19B 2.5B 2.45B 102B 712M 748M 672M 593M 1.06B 64.8B 1.18B 8B 2.96B 27.1B 2.8B 2.75B 114B
Net income -4.03M -4.23M -3.8M -3.36M -6M -367M -6.66M -45.27M -16.77M -153M -15.87M -15.55M -644M 59.46M 62.46M 56.08M 49.53M 88.49M 5.41B 98.2M 668M 247M 2.26B 234M 229M 9.5B
Net Debt 661M 694M 623M 551M 984M 60.14B 1.09B 7.42B 2.75B 25.15B 2.6B 2.55B 106B 663M 697M 625M 552M 987M 60.34B 1.1B 7.45B 2.76B 25.23B 2.61B 2.56B 106B
More financial data * Estimated data

Company Profile

Logo Biotest AG
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Employees
2,426
Sector
Pharmaceuticals
Calendar
2025-03-27 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
25-02-14 28.30 € -2.08% 7,575
25-02-13 28.90 € +0.70% 8,861
25-02-12 28.70 € 0.00% 7,892
25-02-11 28.70 € +0.70% 143
25-02-10 28.50 € -2.06% 4,690

Delayed Quote Xetra, February 14, 2025 at 11:36 am EST

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
28.30EUR
Average target price
37.00EUR
Spread / Average Target
+30.74%
Consensus
Profit revisions
Estimate revisions

Annual profits - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BIO3 Stock